Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Boanmycin for relapsed and refractory multiple myeloma
ChiCTR2200056356Phase 4Not yet recruiting
- Sponsor
- Longgang District People's Hospital of Shenzhen
- Start
- Feb 2022
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of bleomycin A6 in multiple myeloma (MM) (2 arms), sponsored by Longgang District People's Hospital of Shenzhen. Primary endpoint: Objective Response Rate. Planned start Feb 2022; status: not yet recruiting.
02
Drugs
bleomycin A6
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ChiCTR2200056356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200056356.